Valeant beats profit estimate on Bausch along with Lomb strength

Valeant Pharmaceuticals reported a better-than-expected quarterly profit on strength in its Bausch along with Lomb eye-care business, along with the Canadian drugmaker maintained its full-year adjusted earnings forecast.

The company’s U.S.-listed shares were up 16 percent in premarket trading on Tuesday.

Valeant maintained its forecast for full-year adjusted earnings before interest, taxes, depreciation, along with amortization of $3.60 billion to $3.75 billion, even as This particular divests assets to reduce its debt pile, accumulated during former CEO Michael Pearson’s deal-producing spree.

The company said on Tuesday This particular reduced total debt by about $6 billion between the end of the first quarter of 2016 along with Nov. 7. The company said total long-term debt, net of unamortized discounts along with issuance costs, stood at $27.14 billion.

Laval, Quebec-based Valeant also said This particular had eliminated all long-term debt maturities until 2020 along with all mandatory amortization requirements.

“Valeant will be a very different company today than This particular was a year ago … We realize there will be more progress to be made,” Chief Executive Joseph Papa said in a statement.

The company has been rebuilding its business after coming under fire for its steep drug cost hikes along with the unorthodox use of a specialty pharmacy to boost sales.

Net income attributable to Valeant was $1.30 billion, or $3.69 per share, inside third quarter ended Sept. 30, compared using a loss of $1.22 billion, or $3.49 per share, a year earlier.

The reported quarter included a tax benefit of about $1.4 billion, the company said.

Excluding items, the company earned $1.04 per share, according to Thomson Reuters I/B/E/S calculation, above analysts’ average estimate of 88 cents.

Total revenue fell 10.5 percent to $2.22 billion, largely due to volume decreases in its U.S. diversified products along with branded businesses, yet beat the estimate of $2.15 billion.

Valeant’s U.S. shares are down 17 percent This particular year.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

11 − six =